LadRx Corporation

LADX

US2328287071

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:58:43 03/07/2024 BST			5-day change	1st Jan Change
2.24 ^USD	-6.37%		-13.18%	+72.31%

06-04	LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License	CI
05-15	LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

CytRx Corporation Promotes Daniel Levitt to Executive Vice President

January 03, 2013 at 01:30 pm

CytRx Corporation has named Daniel Levitt, M.D., Ph.D., to the newly created position of Executive Vice President. Dr. Levitt will continue to serve as Chief Medical Officer.

Latest news about LadRx Corporation

LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License	06-04	CI
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	01-11	DJ
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
LadRx Corporation has filed an IPO in the amount of $24 million.	14/04/23	CI
LadRx Highlights Patent Issued for Its LADR Technology	27/03/23	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23	CI
LadRx Corporation Auditor Raises 'Going Concern' Doubt	19/03/23	CI
LadRx Announces Review of Strategic Alternatives	15/03/23	CI
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
LadRx Corporation will Change its Ticker to LADX from CYTR	06/10/22	CI
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI
CytRx Corporation Appoints Cary J. Claiborne to its Board of Directors and as Member of Audit Committee and Chairperson of Compensation Committee	09/08/22	CI
CytRx Corporation Announces Director Changes	02/06/22	CI
CytRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
CytRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	23/03/22	CI
CytRx Corporation Auditor Raises 'Going Concern' Doubt	22/03/22	CI
CytRx Corporation Announces Board Retirements	09/03/22	CI
Sector Update: Health Care Stocks Carried Back Near Even by Biotechs	24/02/22	MT
Cytrx Corporation Announces Changes to its Board	03/01/22	CI
CytRx Corporation Announces Executive Changes, Effective January 10, 2022	03/01/22	CI

LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Companyâs linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LADRX CORPORATION	+72.31%	1.11M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B